GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of NVAX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Wednesday for Novavax
(Updated on Apr 17, 2024)

Sell candidate since Apr 10, 2024 Loss -8.69% PDF

The Novavax stock price fell by -2.51% on the last day (Wednesday, 17th Apr 2024) from $3.99 to $3.89. It has now fallen 4 days in a row. During the last trading day the stock fluctuated 4.38% from a day low at $3.88 to a day high of $4.05. The price has fallen in 8 of the last 10 days and is down by -14.32% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -20 thousand shares and in total, 4 million shares were bought and sold for approximately $14.23 million.

Given the current short-term trend, the stock is expected to rise 10.27% during the next 3 months and, with a 90% probability hold a price between $4.29 and $7.01 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

NVAX Signals & Forecast

There are few to no technical positive signals at the moment. The Novavax stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $4.18 and $4.80. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, February 27, 2024, and so far it has fallen -35.38%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Novavax stock

Novavax finds support from accumulated volume at $3.79 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.170 between high and low, or 4.38%. For the last week, the stock has had daily average volatility of 5.02%.

Novavax is oversold on RSI14 (6). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (NVAX) For The Upcoming Trading Day Of Thursday 18th

For the upcoming trading day on Thursday, 18th we expect Novavax Inc to open at $3.94, and during the day (based on 14 day Average True Range), to move between $3.62 and $4.16, which gives a possible trading interval of +/-$0.269 (+/-6.91%) up or down from last closing price. If Novavax Inc takes out the full calculated possible swing range there will be an estimated 13.82% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $3.93 (1.03%) than the support at $3.79 (2.57%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Novavax Inc stock A Buy?

The Novavax stock holds several negative signals and despite the positive trend, we believe Novavax will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -1.063 Sell Candidate Unchanged

Predicted Opening Price for Novavax Inc of Thursday, April 18, 2024

Fair opening price April 18, 2024 Current price
$3.94 ( 1.29%) $3.89

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for NVAX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.11 5.66 %
R2 4.05 3.99 %
R1 4.00 2.95 %
Current price: 3.89
Support S1 3.88 -0.384 %
S2 3.83 -1.42 %
S3 3.77 -3.08 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 4.41 13.37 %
R2 4.03 3.60 %
R1 3.93 1.03 %
Current price 3.89
Support S1 3.79 -2.57%
S2 3.78 -2.83%
S3 3.76 -3.34%

FAQ

What is the symbol for Novavax Stock and on which exchange is it traded?
The symbol for Novavax is NVAX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Novavax Stock?
The Novavax stock holds several negative signals and despite the positive trend, we believe Novavax will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Novavax Stock?
Novavax Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Novavax Stock.

What's the current price of Novavax Stock?
As of the end of day on the 2024-04-17, the price of an Novavax (NVAX) share was $3.89.

What is the 52-week high and low for Novavax Stock?
The 52-week high for Novavax Stock is $11.36 and the 52-week low is $3.53.

What is the market capitalization of Novavax Stock?
As of the 2024-04-17, the market capitalization of Novavax is 576.606M.

When is the next earnings date for Novavax?
The upcoming earnings date for Novavax is May 14, 2024.
Click to get the best stock tips daily for free!

About Novavax Inc

Novavax Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria... NVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT